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The human body has a number of defense mechanisms that kick in under the threat of foreign 
antigens, and one of the more important ones is the activation of white blood cells called T cells. A 
subset of these white blood cells, which attack virus-infected cells and tumor cells, expresses the 
glycoprotein CD8 at their surfaces, and are consequently called CD8+ or cytotoxic T cells. Although 
our immune systems capably manage a multitude of potentially harmful situations, even the best of 
frameworks need some external support on occasion. Among the more troublesome conditions is 
cancer, which has a particularly nasty way of hiding from its antagonists, necessitating sophisticated 
methods for boosting T cells to operate more efficiently. 
In a recent publication in Journal for Immunotherapy of Cancer, Fred Hutch's Dr. Seth Pollack 
demonstrated a promising technique for enabling so called adoptive T cell therapy of various tumor 
types. Adoptive T cell therapy is a seemingly simple concept: T lymphocytes are taken from the 
patient's own body, multiplied and possibly modified ex vivo, and then re-infused into the patient. For 
instance, cells can be engineered with so called chimeric antigen receptors (CAR) and T cell 
receptors (TCR), which have been tested against various cancers demonstrating great promise for 
this new treatment modality. However, the practical use is unfortunately limited by the regulatory and 
logistical burdens following gene transfer approaches. 
Another possibility is to explore the patient's blood and fish out any available T cells that are 
inherently antigen-specific, expand them, and subsequently re-introduce them to the patient. The 
feasibility of this endogenous T cell therapy has been proven for certain tumor antigens, but for 
other, more commonly expressed ones, the approach has been less successful due to low numbers 
of circulating antigen-specific cytotoxic T cells. Dr. Pollack and colleagues from the Clinical 
Research Division wanted to explore this track and chose to focus their efforts on NY-ESO-1, an 
antigen that is expressed in breast, lung and ovarian cancer, as well as in melanoma and sarcoma. 
They developed a strategy that exploits one of their previous discoveries: that the signaling protein 
interleukin-21 can aid the multiplication of T cells (Li et al., 2005). 
Six patients with NY-ESO-1-expressing sarcomas (either synovial sarcoma or myoxid/round cell 
liposarcoma) were selected for the study, and their white blood cells harvested through 
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leukapheresis; a process which separates leukocytes from blood, the remainder of which is returned 
to the patient. Using an NY-ESO-1 tetramer they were able to sort the cells after stimulation, 
isolating the desired NY-ESO-1-specific cytotoxic T cells, which were then successfully expanded 
further to therapeutically relevant levels (> 20 billion cells). Their function was evaluated through 
specific lysis of T2 cells pulsed with varying concentrations of NY-ESO-1 peptide, in addition to an 
NY-ESO-1-expressing cell line (Mel A375). The results were clear: "The cells are capable of 
recognizing and killing tumor cells," Dr. Pollack said. NY-ESO-1-negative control cells (Mel 526) 
were not lysed to the same degree, demonstrating specificity of the produced cells. 
The approach enables isolation and expansion of rare tumor-targeting cytotoxic T cells from 
peripheral blood under clinical manufacturing conditions, thereby opening a sought-after door for 
endogenous T cell therapy. In fact, a clinical trial of this kind of adoptive T cell therapy is already 
underway. Dr. Pollack: "We've treated six patients with tumor-specific T cells expanded using this 
method so far. A new trial starting soon will combine these cells with tumor-directed radiation in an 
effort to increase the efficacy of the T cells by manipulating the tumor microenvironment." 
But it doesn't stop there; the process is easily adapted to other targets as well. "We've also used 
these methods to make cells specific for MAGE and PRAME family antigens," Dr. Pollack said. 
Exciting tidings for anyone who's on the lookout for new wings to add to the collective anti-cancer 
forces; rare birds are ready to get recruited. 
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Image provided by Dr. Seth Pollack 
Schematic of the production of NY-ESO-1-specific T cells from 
patient blood. A) Flow analysis with CD8 and tetramer staining of 
untreated mononuclear cells from peripheral blood showed no 
detectable population of the desired cells. B) After stimulation 
with peptide pulsed dendritic cells, 3/144 wells revealed modest 
populations. C) Cells in the positive wells were sorted and 
expanded. D) The produced T cells successfully lysed peptide 
pulsed targets and NY-ESO-1-expressing tumor cells, but not 
control cells. 
 
